CT-P13 SC Auto-Injector + Placebo Auto-Injector
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderately to Severely Active Rheumatoid Arthritis
Conditions
Moderately to Severely Active Rheumatoid Arthritis
Trial Timeline
Jan 3, 2025 → Apr 15, 2026
NCT ID
NCT06738719About CT-P13 SC Auto-Injector + Placebo Auto-Injector
CT-P13 SC Auto-Injector + Placebo Auto-Injector is a phase 3 stage product being developed by Celltrion for Moderately to Severely Active Rheumatoid Arthritis. The current trial status is active. This product is registered under clinical trial identifier NCT06738719. Target conditions include Moderately to Severely Active Rheumatoid Arthritis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06738719 | Phase 3 | Active |
Competing Products
7 competing products in Moderately to Severely Active Rheumatoid Arthritis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Afimkibart + Placebo | Roche | Phase 3 | 77 |
| Afimkibart | Roche | Phase 3 | 77 |
| Afimkibart | Roche | Phase 3 | 77 |
| Obefazimod | Abivax | Phase 2 | 49 |
Other Products from Celltrion
Azathioprine + PlaceboApproved
85
Infliximab CT-P13 + Immunosuppressors (Thiopurines or Methotrexate)Approved
85
Infliximab + Infliximab + InfliximabApproved
85
Pioglitazone + Alogliptin + Alogliptin + Metformin + DapagliflozinApproved
85
Pioglitazone 15 MG [Actos] + Empagliflozin 10 MG [Jardiance] + Empagliflozin 10 MG [Jardiance] + Pioglitazone 15 MG [Actos]Approved
85